Brief: Allovir Reports First Quarter 2023 Financial Results
04/05/2023 12:13
Allovir Inc ALVR.O :
* ALLOVIR REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
* ALLOVIR INC - FOR FISCAL YEAR 2023, EXPECTS OPERATING
EXPENSES
TO BE IN RANGE OF $150 MILLION TO $170 MILLION, EXCLUDING
NON-CASH EXPENSES
Source text for Eikon: ID:nBw7pNcVba
Further company coverage: ALVR.O
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million